Back to Browse Journals » Neuropsychiatric Disease and Treatment » Volume 4 » Issue 6

Is schizoaffective disorder a distinct categorical diagnosis? A critical review of the literature

Authors Daniel J Abrams, Donald C Rojas, David B Arciniegas

Published Date November 2008 Volume 2008:4(6) Pages 1089—1109

DOI http://dx.doi.org/10.2147/NDT.S4120

Published 27 November 2008

Daniel J Abrams1, Donald C Rojas1, David B Arciniegas1,2

1Department of Psychiatry; 2Neurobehavioral Disorders Program, Departments of Psychiatry and Neurology, University of Colorado School of Medicine, Denver, CO, USA

Abstract: Considerable debate surrounds the inclusion of schizoaffective disorder in psychiatric nosology. Schizoaffective disorder may be a variant of schizophrenia in which mood symptoms are unusually prominent but not unusual in type. This condition may instead reflect a severe form of either major depressive or bipolar disorder in which episode-related psychotic symptoms fail to remit completely between mood episodes. Alternatively, schizoaffective disorder may reflect the co-occurrence of two relatively common psychiatric illnesses, schizophrenia and a mood disorder (major depressive or bipolar disorder). Each of these formulations of schizoaffective disorder presents nosological challenges because the signs and symptoms of this condition cross conventional categorical diagnostic boundaries between psychotic disorders and mood disorders. The study, evaluation, and treatment of persons presently diagnosed with schizoaffective may be more usefully informed by a dimensional approach. It is in this context that this article reviews and contrasts the categorical and dimensional approaches to its description, neurobiology, and treatment. Based on this review, an argument for the study and treatment of this condition using a dimensional approach is offered.

Keywords: schizoaffective disorder, schizophrenia, bipolar disorder, manic-depressive disorder

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Enzyme-responsive nanocomposites for wound infection prophylaxis in burn management: in vitro evaluation of their compatibility with healing processes

Grützner V, Unger RE, Baier G, Choritz L, Freese C, Böse T, Landfester K, Kirkpatrick CJ

International Journal of Nanomedicine 2015, 10:4111-4124

Published Date: 24 June 2015

Noninvasive detection of macrophages in atherosclerotic lesions by computed tomography enhanced with PEGylated gold nanoparticles

Qin J, Peng C, Zhao B, Ye K, Yuan F, Peng Z, Yang X, Huang L, Jiang M, Zhao Q, Tang G, Lu X

International Journal of Nanomedicine 2014, 9:5575-5590

Published Date: 2 December 2014

Development of PLGA-based itraconazole injectable nanospheres for sustained release

Bian X, Liang S, John J, Hsiao CH, Wei X, Liang D, Xie H

International Journal of Nanomedicine 2013, 8:4521-4531

Published Date: 21 November 2013

Preparation and characterization of gadolinium-loaded PLGA particles surface modified with RGDS for the detection of thrombus

Zhang Y, Zhou J, Guo D, Ao M, Zheng Y, Wang Z

International Journal of Nanomedicine 2013, 8:3745-3756

Published Date: 1 October 2013

Dosing frequency and adherence in chronic psychiatric disease: systematic review and meta-analysis

Medic G, Higashi K, Littlewood KJ, Diez T, Granström O, Kahn RS

Neuropsychiatric Disease and Treatment 2013, 9:119-131

Published Date: 16 January 2013

Ultrasmall superparamagnetic iron oxide (USPIO)-based liposomes as magnetic resonance imaging probes

Frascione D, Diwoky C, Almer G, Opriessnig P, Vonach C, Gradauer K, Leitinger G, Mangge H, Stollberger R, Prassl R

International Journal of Nanomedicine 2012, 7:2349-2359

Published Date: 9 May 2012

Combination of TRAIL and actinomycin D liposomes enhances antitumor effect in non-small cell lung cancer

Guo LG, Fan L, Ren JF, Pang Z, Ren Y, Li J, Wen Z, Qian Y, Zhang L, Ma H, Jiang X

International Journal of Nanomedicine 2012, 7:1449-1460

Published Date: 19 March 2012

Once-daily treatment of ADHD with guanfacine: patient implications

Brandon C Strange

Neuropsychiatric Disease and Treatment 2008, 4:499-506

Published Date: 30 June 2008

Role of pregabalin in the treatment of generalized anxiety disorder

David S Baldwin, Khalil Ajel

Neuropsychiatric Disease and Treatment 2007, 3:185-191

Published Date: 8 June 2007